Overview
Lobbying Costs
100,000€ - 199,999€
Financial year: Jan 2022 - Dec 2022
Lobbyists (Full time equivalent)
1 Fte (1)
Lobbyists with EP accreditation
0
High-level Commission meetings
2
Lobbying Costs over the years
-
Info
Valneva
EU Transparency Register
116284040570-75 First registered on 04 Dec 2020
Goals / Remit
Valneva is a specialty vaccine company focused on prevention against diseases with major unmet needs. The Company has several vaccines in development including vaccines against Lyme diseaseand chikungunya (the latter having received approval by US FDA in 2023). Valneva’s portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC.
Main EU files targeted
Given Valneva’s experience in emerging diseases, the company’s business is actually or potentially affected by most of the policies related to Public Health, Research and Innovation. More specifically: Horizon Europe (Horizon 2020), EU4Health, Cross Border Health Threats Regulation, Pharmaceutical Strategy, New Industrial Strategy for Europe, Union Civil Protection Mechanism, HERA, EU FAB, European Critical Medicines Alliance.
Address
Head Office
6 rue Alain Bombard
Saint-Herblain 44800
FRANCEEU Office
Campus Vienna Biocenter 3
Wien 1030
AUSTRIAWebsite
-
People
Total lobbyists declared
1
Employment time Lobbyists 100% 1 Lobbyists (Full time equivalent)
1
Lobbyists with EP accreditation
No lobbyists with EP accreditations
Complementary Information
Valneva created in 2023 a Government Affairs function, albeit with only one person in charge for global activities and also acting for Europe. This position is therefore supported on EU policy affairs by several members of the team are overseeing the activities on ad hoc basis.
Person in charge of EU relations
Data not provided by Register Secretariat due to GDPR
Person with legal responsibility
Data not provided by Register Secretariat due to GDPR
-
Categories
Category
Companies & groups
-
Networking
Affiliation
Vaccines Europe
France Biotech
Pharmig - Verband der pharmazeutischen Industrie Österreichs
ÖVIH - Österreichischer Verband der Impfstoffhersteller
WKÖ - Austrian Federal Economic Chamber
Industriellenvereinigung (Vereinigung der Österreichischen Industrie)
Signatary of UN Global Compact
LIF - Läkemedelsindustriföreningens
LEEM - Les Entreprises du Médicament
ABPI UK - The Association of the British Pharmaceutical Industry
Royal Society of Biology (UK)
Biotechnology Innovation Organization (BIO, USA)
Adult Vaccine Access Coalition (AVAC, USA)
Medical Countermeasures Coalition (MC2, USA)Member organisations
None declared
-
Financial Data
Interests represented
Promotes their own interests or the collective interests of their members
Closed financial year
Jan 2022 - Dec 2022
Lobbying costs for closed financial year
100,000€ - 199,999€
Major contributions in closed year
None declared
Intermediaries for closed year
Name Amount fipra international srl 50,000€ - 99,999€ Intermediaries for current year
Name fipra international srl Closed year Costs
100,000€ - 199,999€
Other financial info
None declared
-
EU Structures
Groups (European Commission)
none
Groups (European Parliament)
N/A
Communication activities
Starting shot for vaccines. Early lessons from the ups and downs of COVID-19 immunisation roll-out(s) - in cooperation with European Health Forum Gastein (2021)
"Outbreak Diseases: a sudden risk, a constant threat” - Event in the European Parliament to address preparedness for outbreak diseases.Other activities
None declared
Meetings
Meetings
2 meetings found. Download meetings
The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.
-
Date 13 Mar 2023 Location Brussels Subject Valneva updated HERA on their products available and in development. DG Health Emergency Preparedness and Response Authority Attending - Pierre Delsaux (Director-General)
-
Date 02 Mar 2021 Location Videoconference Subject Vaccine production Cabinet Cabinet of Commissioner Thierry Breton Portfolio Internal Market Attending - Thierry Breton (Commissioner)
Other Lobbyists